Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

NCT02088060
completedphase_3

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

NCT01617187
completedphase_2

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCT02161718
completedphase_3

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200

Clinical Trials (4)

Showing 4 of 4 trials
NCT02088060Phase 2

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

Terminated
NCT01617187Phase 3

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

Completed
NCT02161718Phase 2

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

Completed
NCT01617200Phase 3

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4